Surgery is becoming a viable treatment option for an increasing proportion of patients with low-grade gliomas, but there is a lack of class I evidence to support its efficacy. In this Review, Pouratianet al. critically analyze the utility of surgery in low-grade glioma. They highlight recent technological advances that have made this approach safer and more accessible, and consider the challenges involved in designing trials to assess the extent to which aggressive resection improves prognosis.
- Nader Pouratian
- Ashok Asthagiri
- David Schiff
